{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = 1-[(8''S'',9''S'',10''R'',13''S'',14''S'',17''S'')-3-cyclopentyloxy-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1''H''-cyclopenta[''a'']phenanthren-17-yl]ethanone
| image = Quingestrone.svg
| width = 250

<!--Clinical data-->
| tradename = Enol-Luteovis
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 67-95-8
| CAS_supplemental = 
| ATC_prefix = G03
| ATC_suffix = A
| PubChem = 9929903
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 8105534
| UNII = 0612VZ9I5Z
| ChEMBL = 2104568
| KEGG = D05680

<!--Chemical data-->
| C=26 | H=38 | O=2
| molecular_weight = 382.57872 g/mol
| SMILES = CC(=O)C1CCC2C1(CCC3C2CC=C4C3(CCC(=C4)OC5CCCC5)C)C
| StdInChI_Ref = 
| StdInChI = 1S/C26H38O2/c1-17(27)22-10-11-23-21-9-8-18-16-20(28-19-6-4-5-7-19)12-14-25(18,2)24(21)13-15-26(22,23)3/h8,16,19,21-24H,4-7,9-15H2,1-3H3/t21-,22+,23-,24-,25-,26+/m0/s1
| StdInChIKey_Ref = 
| StdInChIKey = XAVRSHOUEXATJE-FBQZJRKBSA-N
| synonyms = W-3399; Progesterone 3-cyclopentyl enol ether; PCPE; 3-Cyclopentyloxypregna-3,5-dien-20-one
}}
{{Distinguish|quingestanol}}

'''Quingestrone''' (brand name '''Enol-Luteovis'''; former developmental code name '''W-3399'''), is a pure [[progestogen]] closely related to [[progesterone]] which was developed by Vister and marketed in [[Italy]] as an [[oral contraceptive]] (in combination with [[ethinylestradiol]] or [[mestranol]]).<ref name="pmid3559100">{{cite journal | title=Prolonged cholestasis after cyproheptadine-induced acute hepatitis | journal=J. Clin. Gastroenterol. | vauthors=Larrey D, Geneve J, Pessayre D, Machayekhi JP, Degott C, Benhamou JP | year=1987 | volume=9 | issue=1 | pages=102–4 | pmid=3559100 | ISSN=0192-0790 | doi=10.1097/00004836-198702000-00026}}</ref><ref name="Group1965">{{cite book | url=https://books.google.com/books?id=-5hsAAAAMAAJ | title=Handbook on oral contraception | publisher=Little, Brown | author=International Planned Parenthood Federation. Medical Committee. Oral Advisory Group | year=1965 | page=18 | OCLC=2717593}}</ref><ref name="Elks2014">{{cite book | DOI=10.1007/978-1-4757-2085-3 | url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=RA1-PA129 | title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies | publisher=Springer | date=14 November 2014 | author=J. Elks | page=163 | isbn=978-1-4757-2085-3 | OCLC=898564124}}</ref><ref name="Juo2001">{{cite book | url=https://books.google.com/books?id=Y4DLBQAAQBAJ&pg=PA922 | title=Concise Dictionary of Biomedicine and Molecular Biology | publisher=CRC Press | date=21 December 2001 | author=Pei-Show Juo | pages=922– | isbn=978-1-4200-4130-9 | LCCN=2001043892 | OCLC=48057162}}</ref><ref name="Hawkins1974">{{cite book|author=Denis Frank Hawkins|title=Obstetric therapeutics: clinical pharmacology and therapeutics in obstetric practice|url=https://books.google.com/books?id=osNsAAAAMAAJ|year=1974|publisher=Baillière Tindall|isbn=978-0-7020-0471-1|pages=129, 138, 145}}</ref><ref name="Bentley1980">{{cite book|author=P. J. Bentley|title=Endocrine Pharmacology: Physiological Basis and Therapeutic Applications|url=https://books.google.com/books?id=W6M9AAAAIAAJ&pg=PA274|year=1980|publisher=CUP Archive|isbn=978-0-521-22673-8|pages=274–}}</ref><ref name="Watts1962">{{cite journal|last1=Watts|first1=GeorgeT.|title=EMERGENCY TREATMENT OF POISONING|journal=The Lancet|volume=279|issue=7228|year=1962|pages=533–534|issn=0140-6736|doi=10.1016/S0140-6736(62)91504-0}}</ref>

==Pharmacology==
Along with the [[retroprogesterone]] derivative [[dydrogesterone]], quingestrone is described as a "true" progesterone derivative or [[progestogen]] due to its close similarity to natural progesterone.<ref name="Wachtel1969">{{cite book | url=https://books.google.com/books?id=AcRsAAAAMAAJ | title=Exfoliative cytology in gynaecological practice | publisher=Appleton-Century-Crofts | author=Erica G. Wachtel | year=1969 | page=134 | LCCN=77008744}}</ref> Similarly to progesterone, dydrogesterone, and [[hydroxyprogesterone caproate]], quingestrone is a pure progestogen and lacks any [[androgen]]ic effects.<ref name="BairdKerr1969">{{cite book | author1=Dugald Baird | url=https://books.google.com/books?id=jbwwAAAAIAAJ | title=Combined textbook of obstetrics and gynæcology for students and practitioners | publisher=E. & S. Livingstone | author2=John Martin Munro Kerr | year=1969 | LCCN=70360656}}</ref> As such, it poses no risk of androgenic [[side effect]]s or [[virilization|virilizing]] [[teratogen]]ic effects on female fetuses.<ref name="BairdKerr1969" /> Accordingly, the drug was studied in the clinical prevention of [[miscarriage]] during [[pregnancy]]; however, insufficient efficacy was observed at the dosage assessed (100&nbsp;mg/day orally).<ref name="BurtonWachtel1967" /><ref>{{cite book|title=Vitamins and Hormones|url=https://books.google.com/books?id=rhbTtjo7dM4C&pg=PA332|date=9 February 1973|publisher=Academic Press|isbn=978-0-08-086627-7|pages=332–}}</ref><ref name="Fraser1998">{{cite book|author=Ian S. Fraser|title=Estrogens and Progestogens in Clinical Practice|url=https://books.google.com/books?id=eO5qAAAAMAAJ|year=1998|publisher=Churchill Livingstone|isbn=978-0-443-04706-0}}</ref><ref name="GoldsteinBerrier1989">{{cite journal | first1=Peter | last1=Goldstein | title=A meta-analysis of randomized control trials of progestational agents in pregnancy | last2=Berrier | first2=Jayne | last3=Rosen | first3=Scott | last4=Sacks | first4=Henry S. | last5=Chalmers | first5=Thomas C. | journal=BJOG: An International Journal of Obstetrics and Gynaecology | year=1989 | volume=96 | issue=3 | pages=265–274 | issn=1470-0328 | doi=10.1111/j.1471-0528.1989.tb02385.x | pmid=2653414}}</ref> Quingestrone is said to influence the [[hypothalamic–pituitary–adrenal axis]] similarly to [[progesterone]] and [[medroxyprogesterone acetate]], producing [[adrenal suppression]] at sufficiently high doses, and this suggests that it possesses weak [[glucocorticoid]] activity similarly to progesterone.<ref name="Martini1966">{{cite book | url=https://books.google.com/books?id=mp3wAAAAMAAJ | title=Neuroendocrinology | publisher=Academic Press | author=Luciano Martini | year=1966 | page=331 | LCCN=66026256}}</ref><ref name="SteinetzBeach1965">{{cite journal|last1=Steinetz|first1=B.G.|last2=Beach|first2=V.L.|last3=DiPasquale|first3=G.|last4=Battista|first4=J.V.|title=Effects of different gestagenic steroid types on plasma-free corticosteroid levels in ACTH-treated rats|journal=Steroids|volume=5|issue=1|year=1965|pages=93–108|issn=0039-128X|doi=10.1016/0039-128X(65)90134-0}}</ref>

==Pharmacokinetics==
Quingestrone has been suggested to act as a [[prodrug]] of progesterone via slow [[hydrolysis]] in the body.<ref name="BurtonWachtel1967">{{cite journal | first1=Eunice R. | last1=Burton | title=A CLINICAL TRIAL AND CYTOLOGICAL ASSESSMENT OF ENOL LUTEOVIS IN THE TREATMENT OF THREATENED AND RECURRENT ABORTION | last2=Wachtel | first2=Erica G. | journal=BJOG: An International Journal of Obstetrics and Gynaecology | year=1967 | volume=74 | issue=4 | pages=533–536 | issn=1470-0328 | doi=10.1111/j.1471-0528.1967.tb03986.x | pmid=5340429}}</ref><ref name="CharmanPorter1996">{{cite journal|last1=Charman|first1=William N.|last2=Porter|first2=Christopher J.H.|title=Lipophilic prodrugs designed for intestinal lymphatic transport|journal=Advanced Drug Delivery Reviews|volume=19|issue=2|year=1996|pages=149–169|issn=0169-409X|doi=10.1016/0169-409X(95)00105-G}}</ref> Indeed, it produces similar [[metabolite]]s (e.g., [[pregnanediol]]s and [[allopregnanediol]]s) as progesterone,<ref name="BurtonWachtel1967" /><ref name="pmid18472981">{{cite journal | vauthors = Fatouros DG, Karpf DM, Nielsen FS, Mullertz A | title = Clinical studies with oral lipid based formulations of poorly soluble compounds | journal = Ther Clin Risk Manag | volume = 3 | issue = 4 | pages = 591–604 | year = 2007 | pmid = 18472981 | pmc = 2374933 | doi = | url = }}</ref> although with differing ratios,<ref>http://www.popline.org/node/474452</ref><ref name="Hawkins1974" /> and notably is the only progestin that is known to produce pregnanediol as a metabolite.<ref name="CurrentMedicineAndDrugs1962">{{cite book | url=https://books.google.com/books?id=auc1AQAAIAAJ | title=Current Medicine and Drugs | year=1962 | quote=Enol Luteovis (3 cyclo-pentyl enol ether of progesterone) is the only oral progestin producing pregnanediol as a metabolite. It is not very potent and probably carries very little risk of producing virilizing effects on a female foetus. Thus it is more closely related to progesterone than the other synthetic progestins. | ISSN=0590-4048}}</ref> Subsequent research has cast doubt on the notion that quingestrone is a prodrug of progesterone however, and indicates that it instead is directly [[metabolism|metabolized]] into pregnanediols without [[metabolic intermediate|intermediate]] conversion into progesterone.<ref name="MeliWolff1965">{{cite journal|last1=Meli|first1=A.|last2=Wolff|first2=A.|last3=Lucker|first3=W. E.|last4=Steinetz|first4=B. G.|title=The Biological Profile of Progesterone 3-Cyclopentyl Enol Ether as Compared with That of Progesterone|journal=Experimental Biology and Medicine|volume=118|issue=3|year=1965|pages=714–717|issn=1535-3702|doi=10.3181/00379727-118-29947}}</ref>

Relative to progesterone, quingestrone shows improved [[pharmacokinetics]], including higher [[potency (pharmacology)|potency]],<ref>http://www.popline.org/node/474452</ref> [[oral administration|oral activity]],<ref name="Lee1965">{{cite book | url=https://books.google.com/books?id=IhU-AQAAIAAJ | title=The ... Year Book of Obstetrics and Gynecology | publisher=Year Book Publishers | author=Joseph Bolivar De Lee | year=1965 | page=150 | ISSN=0084-3911 | LCCN=cdr38000020}}</ref> and a longer [[terminal half-life]] and hence [[duration of action]].<ref name="CharmanPorter1996" /> This is considered to be due to its higher [[lipophilicity]],<ref name="CharmanPorter1996" /> being stored into and slowly released from [[fat]].<ref name="Bentley1980" /><ref name="BurtonWachtel1967" /> Quingestrone also shows slower [[metabolism]] and more stable blood levels, with a longer time to peak concentrations and a less intense peak compared to progesterone.<ref name="CaieKlopper1964">{{cite journal | first1=E. | last1=Caie | title=THE URINARY EXCRETION OF PREGNANEDIOL AFTER THE ADMINISTRATION OF AN ORAL GESTAGEN (PROGESTERONE CYCLOPENTYL ENOL ETHER) | last2=Klopper | first2=A. | journal=Journal of Endocrinology | year=1964 | volume=28 | issue=2 | pages=221–222 | issn=0022-0795 | doi=10.1677/joe.0.0280221 | pmid=14112260}}</ref> The [[bioavailability]] of quingestrone is highest when it is given as a [[sesame seed oil]] solution (compared to an oil suspension (~2-fold less) or [[micronization]] (~7-fold less)).<ref name="pmid18472981" />

==Chemistry==
{{See also|List of steroidal progestogens|Progestogen ester#Progestogen ethers}}

Quingestrone, also known as '''progesterone 3-cyclopentyl enol ether''' ('''PCPE''') or as '''3-cyclopentyloxypregna-3,5-dien-20-one''', is a [[synthetic compound|synthetic]] [[pregnane]] [[steroid]] and a [[chemical derivative|derivative]] of [[progesterone]].<ref name="Elks2014" /> It is specifically the C3 [[cyclopentane|cyclopentyl]] [[enol]] [[ether]] of progesterone.<ref name="Elks2014" /> Quingestrone is closely related to [[pentagestrone acetate]] (17α-acetoxyprogesterone 3-cyclopentyl enol ether).<ref name="Elks2014" />

==History==
Quingestrone was introduced in [[Italy]] in 1962.

==Society and culture==

===Generic name===
''Quingestrone'' is the [[generic term|generic name]] of the drug and its {{abbrlink|INN|International Nonproprietary Name}} and {{abbrlink|USAN|United States Adopted Name}}.<ref name="Elks2014" />

==See also==
* [[Quingestanol acetate]]
* [[Progestogen ester]]

==References==
{{Reflist|2}}


{{Progestogens and antiprogestogens}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Glucocorticoid receptor modulators}}
{{Progesterone receptor modulators}}
{{Xenobiotic-sensing receptor modulators}}
}}

[[Category:Cyclopentanes]]
[[Category:Ethers]]
[[Category:Glucocorticoids]]
[[Category:Hormonal contraception]]
[[Category:Pregnanes]]
[[Category:Progestogens]]